Justin Gainor, MD, and Alexander Drilon, MD, provide their perspectives on the balance between targeted therapy and immuno-oncology, particularly how checkpoint inhibition has shown poor responses in driver mutation non–small cell lung cancer.

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть